Davis Polk advised the representatives of the several underwriters in the offering.Adagio Therapeutics, Inc. executed the initial public offering of 20,930,000 shares of its common stock at $17.00…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
